Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
July 7th, 2009
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) reported the issuance of a U.S. patent with broad claims covering vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent represents the first broad coverage of imaging claims under Peregrine's PS-targeting platform, which includes Peregrine's lead antibody bavituximab. PS is a phospholipid that becomes exposed on the surface of tumor blood vessel cells. Since PS is typically not exposed on the surface of normal tissues, it represents a unique target for the vascular imaging of tumors and tumor metastases in patients with cancer. "PS-targeting antibodies such as bavituximab preferentially...
Source: Cancer Weekly (2009-07-07)
|
